Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PacBio posts a narrower Q3 loss and margin gains, but shares fall as revenues dip amid softer instrument demand.
Although the revenue and EPS for Pacific Biosciences (PACB) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
| Life Sciences Tools & Services Industry | Healthcare Sector | Christian O. Henry CEO | XFRA Exchange | US69404D1081 ISIN |
| US Country | 575 Employees | - Last Dividend | - Last Split | 27 Oct 2010 IPO Date |
Pacific Biosciences of California, Inc., originally known as Nanofluidics, Inc. until its name change in 2005, is a biotechnology firm focused on the design, development, and manufacturing of solutions for sequencing in order to tackle genetically complex problems. Founded in the year 2000 and based in Menlo Park, California, the company has carved a niche for itself in the realm of high-fidelity long-read sequencing technologies. Pacific Biosciences, also known as PacBio, caters to a diverse clienteles such as academic and governmental research institutions, genome centers, public health laboratories, hospitals, clinical research institutes, contract research organizations, as well as entities in the pharmaceutical and agricultural sectors. The company boasts a global presence, marketing its products directly and through distribution partners across Asia, Australia, Europe, the Middle East, Africa, and Latin America. Strategic alliances, like those with Invitae Corporation for development and commercialization, and a collaboration with Radboud University Medical Center for genetics research, are pillars supporting PacBio's innovation and market expansion.
Pacific Biosciences offers sequencing systems renowned for their single molecule real-time (SMRT) technology. This technology allows for the resolution of genetically complex issues through high-fidelity, long-read sequencing capabilities.
The company provides a variety of consumable products for sequencing, including SMRT cells, and reagent kits designed for specific workflows. This includes kits for the preparation of SMRTbell double-stranded DNA libraries, which comprise essential molecular biology reagents necessary for sequencing preparation.
PacBio's binding kits include modified DNA polymerase, crucial for binding SMRTbell libraries to the polymerase in preparation for sequencing. Sequencing kits, on the other hand, contain all necessary reagents for on-instrument real-time sequencing, which includes phospholinked nucleotides.
The Revio and Sequel systems are designed for the conduct, monitoring, and analysis of single-molecule biochemical reactions in real-time, pioneering advancements in the sequencing technologies sector.
Beyond its forte in long-read sequencing, Pacific Biosciences also provides solutions for short-read sequencing (SBB), catering to a broader range of genomic analysis needs.
The Onso instrument is tailored for conducting, monitoring, and analyzing SBB biochemical reactions. Accompanying consumables include flow cells and reagent kits for clustering and sequencing, facilitating comprehensive short-read sequencing processes.